Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Glucose metabolism controls disease-specific signatures of macrophage effector functions
Ryu Watanabe, … , Jörg J. Goronzy, Cornelia M. Weyand
Ryu Watanabe, … , Jörg J. Goronzy, Cornelia M. Weyand
Published October 18, 2018
Citation Information: JCI Insight. 2018;3(20):e123047. https://doi.org/10.1172/jci.insight.123047.
View: Text | PDF
Clinical Medicine Metabolism Vascular biology

Glucose metabolism controls disease-specific signatures of macrophage effector functions

  • Text
  • PDF
Abstract

BACKGROUND. In inflammatory blood vessel diseases, macrophages represent a key component of the vascular infiltrates and are responsible for tissue injury and wall remodeling. METHODS. To examine whether inflammatory macrophages in the vessel wall display a single distinctive effector program, we compared functional profiles in patients with either coronary artery disease (CAD) or giant cell arteritis (GCA). RESULTS. Unexpectedly, monocyte-derived macrophages from the 2 patient cohorts displayed disease-specific signatures and differed fundamentally in metabolic fitness. Macrophages from CAD patients were high producers for T cell chemoattractants (CXCL9, CXCL10), the cytokines IL-1β and IL-6, and the immunoinhibitory ligand PD-L1. In contrast, macrophages from GCA patients upregulated production of T cell chemoattractants (CXCL9, CXCL10) but not IL-1β and IL-6, and were distinctly low for PD-L1 expression. Notably, disease-specific effector profiles were already identifiable in circulating monocytes. The chemokinehicytokinehiPD-L1hi signature in CAD macrophages was sustained by excess uptake and breakdown of glucose, placing metabolic control upstream of inflammatory function. CONCLUSIONS. We conclude that monocytes and macrophages contribute to vascular inflammation in a disease-specific and discernible pattern, have choices to commit to different functional trajectories, are dependent on glucose availability in their immediate microenvironment, and possess memory in their lineage commitment. FUNDING. Supported by the NIH (R01 AR042527, R01 HL117913, R01 AI108906, P01 HL129941, R01 AI108891, R01 AG045779 U19 AI057266, R01 AI129191), I01 BX001669, and the Cahill Discovery Fund.

Authors

Ryu Watanabe, Marc Hilhorst, Hui Zhang, Markus Zeisbrich, Gerald J. Berry, Barbara B. Wallis, David G. Harrison, John C. Giacomini, Jörg J. Goronzy, Cornelia M. Weyand

×

Figure 6

Glucose regulates mitochondrial activity and effector molecule expression.

Options: View larger image (or click on image) Download as PowerPoint
Glucose regulates mitochondrial activity and effector molecule expressio...
(A) Random serum glucose levels measured during clinic visits. Each data point represents 1 CAD or GCA patient. Twelve of 27 CAD patients had diabetes mellitus. (B and C) Ex vivo–differentiated macrophages were stimulated for 24 hours and incubated in glucose-free medium containing 5 μM of the fluorescently labeled D-glucose analog 2-NBDG for 60 minutes. 2-NBDG uptake was quantified by flow cytometry. (B) Representative dot plots. (C) Summary results from 6 HC, 6 GCA patients, 6 statin-treated CAD patients, and 6 CAD patients not on a statin. (D) Ex vivo–differentiated macrophages from healthy individuals were stimulated for 6 hours in the presence of increasing concentrations of glucose. D-Mannitol was used as an osmotic control. Mitochondrial ROS production was measured by flow cytometry. Data are from 6 experiments. (E–G) Ex vivo–differentiated macrophages from HC and GCA were stimulated with LPS/IFN-γ for 6 hours in the absence or presence of glucose. D-Mannitol was used as an osmotic control. Intracellular CXCL10 concentrations (E), intracellular IL-6 concentrations (F), and surface PD-L1 expression (G) were measured by flow cytometry. Summary from 6 independent samples. (H) Freshly isolated monocytes from CAD patients were cultured in high or low glucose concentrations for 6 hours and stimulated with LPS/IFN-γ for 6 hours. Surface GLUT1 expression was quantified by flow cytometry. Summary from 9 (including 4 diabetic) samples. Data are mean ± SEM and were analyzed by Mann-Whitney test (A), 2-way ANOVA with Tukey’s multiple comparison test (C), 1-way ANOVA with Tukey’s multiple comparison test (D–G), or paired t test (H). *P < 0.05; **P < 0.01; ***P < 0.001. CAD, coronary artery disease; CXCL, C-X-C motif chemokine ligand; FMO, fluorescence minus one; GCA, giant cell arteritis; GLUT1, glucose transporter 1; HC, healthy control; IFN-γ, interferon γ; IL, interleukin; LPS, lipopolysaccharide; MFI, mean fluorescence intensity; ns, not significant; PD-L1, programmed death ligand 1; ROS, reactive oxygen species; SSC, side scatter.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts